{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.0","upperLimit":"280.0","value":"81.0"},{"groupId":"OG001","lowerLimit":"29.0","upperLimit":"393.0","value":"64.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"description":"PN is defined as the event in the high-level term of peripheral neuropathies NEC according to the MedDRA. A PN event was considered as resolved if its final outcome was resolved with no subsequent PN event of the same preferred term occurring on the improvement date or the day before and after. Time to improvement was defined as the time from the initial onset date (inclusive) to the improvement of event.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib placebo-matching capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 through 26.","id":"OG000","title":"Placebo"},{"description":"Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 to 4 that may have been escalated to 4 mg thereafter up to Cycle 26.","id":"OG001","title":"Ixazomib"}],"paramType":"MEDIAN","populationDescription":"Safety Population included all participants who received at least 1 dose of ixazomib or placebo. Overall number of participants analyzed are the number of participants with events.","reportingStatus":"POSTED","timeFrame":"Up to 52 months","title":"Time to Improvement of PN Events","type":"SECONDARY","unitOfMeasure":"days"}